Kavuru Vimal Kumar
Directeur/Bestuurslid bij Cronus Pharma Specialities India Pvt Ltd.
Profiel
Kavuru Vimal Kumar has worked as a Director at Cronus Pharma Specialities India Pvt Ltd.
since 2018 and at Casper Pharma Pvt Ltd.
since 2016.
Actieve functies van Kavuru Vimal Kumar
| Bedrijven | Functie | Begin |
|---|---|---|
Cronus Pharma Specialities India Pvt Ltd.
 Cronus Pharma Specialities India Pvt Ltd. Pharmaceuticals: MajorHealth Technology Cronus Pharma Specialities India Pvt Ltd. is an Indian pharmaceutical company that manufactures pharmaceutical products. The private company is based in Hyderabad, India and was founded in 2015. | Directeur/Bestuurslid | 16-07-2018 |
Casper Pharma Pvt Ltd.
 Casper Pharma Pvt Ltd. Pharmaceuticals: MajorHealth Technology Part of Suven Pharmaceuticals Ltd., Casper Pharma Pvt Ltd. is an Indian pharmaceutical company that manufactures pharmaceutical products. The company is based in Hyderabad, India. The company was founded in 2016. Casper Pharma was acquired by Suven Pharmaceuticals Ltd. on June 30, 2022 for $20.75 million. | Directeur/Bestuurslid | 13-01-2016 |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 2 |
|---|---|
Cronus Pharma Specialities India Pvt Ltd.
Cronus Pharma Specialities India Pvt Ltd. Pharmaceuticals: MajorHealth Technology Cronus Pharma Specialities India Pvt Ltd. is an Indian pharmaceutical company that manufactures pharmaceutical products. The private company is based in Hyderabad, India and was founded in 2015. | Health Technology |
Casper Pharma Pvt Ltd.
Casper Pharma Pvt Ltd. Pharmaceuticals: MajorHealth Technology Part of Suven Pharmaceuticals Ltd., Casper Pharma Pvt Ltd. is an Indian pharmaceutical company that manufactures pharmaceutical products. The company is based in Hyderabad, India. The company was founded in 2016. Casper Pharma was acquired by Suven Pharmaceuticals Ltd. on June 30, 2022 for $20.75 million. | Health Technology |
